Evidence map›Paper›PMID 25734734›Full record

Observational studyJAMA2015

The natural history of benign thyroid nodules.

Cosimo Durante, Giuseppe Costante, Giuseppe Lucisano, Rocco Bruno, Domenico Meringolo, Alessandra Paciaroni, Efisio Puxeddu, Massimo Torlontano, Salvatore Tumino, Marco Attard and 3 more

6 registry-linked trialsAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in JAMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 165 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 5 pooled it
29.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298684 phase4unknown statusstarted 2021, after this paper: background citation

Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study

Ran2021Enrolled90Registered outcomes9Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Thyroid Nodule (Benign)ArmsMetformin, Sitagliptin
Open the trial in the graph
NCT03331172 nacompletednot on this mapstarted 2017, after this paper: background citation

Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.

TypeinterventionalSponsorThe University of Hong KongRan2017 to 2018Enrolled28ConditionsThyroid NoduleArmsEchopulse
NCT04009863 nacompletednot on this mapstarted 2020, after this paper: background citation

A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter

TypeinterventionalSponsorThe University of Hong KongRan2020 to 2022Enrolled156ConditionsNon Toxic Multinodular Goiter, High Intensity Focused Ultrasound, RAIArmsEchopulse, Radioactive iodine (Radioidine i131)
NCT05189314 recruitingnot on this mapstarted 2019, after this paper: background citation

Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules

TypeobservationalSponsorColumbia UniversityRan2019 to 2028Enrolled100ConditionsThyroid NodulesArmsThyroidectomy, Radiofrequency Ablation
NCT05189808 recruitingnot on this mapstarted 2020, after this paper: background citation

Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules

TypeobservationalSponsorColumbia UniversityRan2020 to 2028Enrolled50ConditionsIndeterminate Bethesda III Thyroid NodulesArmsRadiofrequency Ablation
NCT05189821 recruitingnot on this mapstarted 2021, after this paper: background citation

RFA Treatment for Papillary Thyroid Microcarcinoma Cohort

TypeobservationalSponsorColumbia UniversityRan2021 to 2028Enrolled50ConditionsPapillary Thyroid MicrocarcinomaArmsRadiofrequency Ablation
3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 5 syntheses or guidelines pooled it, 466 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. The impact of perioperative neck stretching exercises on post-thyroidectomy neck discomfort, voice, and quality of life: a randomized controlled trial.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Cosimo DuranteDipartimento di Medicina Interna e Specialità Mediche, Università di Roma Sapienza, Roma, Italy.
Giuseppe CostanteDipartimento di Scienze della Salute, Università di Catanzaro Magna Graecia, Catanzaro, Italy.
Giuseppe LucisanoCenter for Outcomes Research and Clinical Epidemiology, Pescara, Italy10Dipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università di Bari Aldo Moro, Bari, Italy.
Rocco BrunoUnità di Endocrinologia, Ospedale di Tinchi-Pisticci, Matera, Italy.
Domenico MeringoloUnità Operativa Semplice Dipartimentale di Endocrinologia, Ospedale di Bentivoglio, Bologna, Italy.
Alessandra PaciaroniDipartimento di Medicina Interna e Specialità Mediche, Università di Roma Sapienza, Roma, Italy.
Efisio PuxedduDipartimento di Medicina, Università di Perugia, Perugia, Italy.
Massimo TorlontanoUnità Operativa di Endocrinologia, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Salvatore TuminoDipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy.
Marco AttardUnità Operativa di Endocrinologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Livia LamartinaDipartimento di Medicina Interna e Specialità Mediche, Università di Roma Sapienza, Roma, Italy.
Antonio NicolucciCenter for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
Sebastiano FilettiDipartimento di Medicina Interna e Specialità Mediche, Università di Roma Sapienza, Roma, Italy.
Sapienza University of Rome · ITCenter for Outcomes Research and Clinical Epidemiology · ITCasa Sollievo della Sofferenza · ITMagna Graecia University · ITOspedale Vincenzo Cervello · ITPresidenza Del Consiglio Dei Ministri · ITUniversity of Catania · ITUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceDetection of asymptomatic thyroid nodules has increased. Consensus is lacking regarding the optimal follow-up of cytologically proven benign lesions and sonographically nonsuspicious nodules. Current guidelines recommend serial ultrasound examinations and reassessment of cytology if significant growth is observed.

objectiveTo determine the frequency, magnitude, and factors associated with changes in thyroid nodule size. DESIGN, SETTING, AND

participantsProspective, multicenter, observational study involving 992 consecutive patients with 1 to 4 asymptomatic, sonographically or cytologically benign thyroid nodules. Patients were recruited from 8 hospital-based thyroid-disease referral centers in Italy between 2006 and 2008. Data collected during the first 5 years of follow-up, through January 2013, were analyzed. MAIN OUTCOMES AND MEASURES: Baseline nodule growth (primary end point) was assessed with yearly thyroid ultrasound examinations. Size changes were considered significant for growth if an increase of 20% or more was recorded in at least 2 nodule diameters, with a minimum increase of 2 mm. Baseline factors associated with growth were identified. Secondary end points were the sonographic detection of new nodules and the diagnosis of thyroid cancer during follow-up.

resultsNodule growth occurred in 153 patients (15.4% [95% CI, 14.3%-16.5%]). One hundred seventy-four of the 1567 original nodules (11.1% [95% CI, 10.3%-11.9%]) increased in size, with a mean 5-year largest diameter increase of 4.9 mm (95% CI, 4.2-5.5 mm), from 13.2 mm (95% CI, 12.1-14.2 mm) to 18.1 mm (95% CI, 16.7-19.4 mm). Nodule growth was associated with presence of multiple nodules (OR, 2.2 [95% CI 1.4-3.4] for 2 nodules; OR, 3.2 [95% CI, 1.8-5.6 for 3 nodules; and OR, 8.9 [95% CI, 4.4-18.0] for 4 nodules), main nodule volumes larger than 0.2 mL (OR, 2.9 [95% CI, 1.7-4.9] for volumes >0.2 to <1 mL and OR, 3.0 [95% CI, 1.8-5.1] for volumes ≥1 mL), and male sex (OR, 1.7 [95% CI, 1.1-2.6]), whereas an age of 60 years or older was associated with a lower risk of growth than age younger than 45 years (OR, 0.5 [95% CI 0.3-0.9]). In 184 individuals (18.5% [95% CI, 16.4%-20.9%]), nodules shrank spontaneously. Thyroid cancer was diagnosed in 5 original nodules (0.3% [95% CI, 0.0%-0.6%]). Only 2 had grown. An incidental cancer was found at thyroidectomy in a nonvisualized nodule. New nodules developed in 93 patients (9.3% [95% CI, 7.5%-11.1%]), with detection of one cancer. CONCLUSIONS AND RELEVANCE: Among patients with asymptomatic, sonographically or cytologically benign thyroid nodules, the majority of nodules exhibited no significant size increase during 5 years of follow-up and thyroid cancer was rare. These findings support consideration of revision of current guideline recommendations for follow-up of asymptomatic thyroid nodules.

Indexed as

Disease ProgressionAdultAgedFemaleHumansIncidenceIncidental FindingsLogistic ModelsMaleMiddle AgedProspective StudiesRisk FactorsThyroid NeoplasmsThyroid NoduleUltrasonography

Identifiers

PMID25734734
OpenAlexW2055238778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.